International Journal of Research and Review Vol. 10; Issue: 4; April 2023 Website: www.ijrrjournal.com Research Paper E-ISSN: 2349-9788; P-ISSN: 2454-2237 International Journal of Research and Review (ijrrjournal.com) 491 Volume 10; Issue: 4; April 2023 A Cost Variation Analysis of Hypolipidemic Drugs Available in the Indian Market Ujjawal Rawat 1 , Ambika 2 , Piyush Kumar 3 , Mohd Qasim 4 , Rahul Chauhan 5 , Mohd Mohsin 6 1,2,3,4,5,6 Pharmd Intern, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001 Corresponding Author: Ujjawal Rawat DOI: https://doi.org/10.52403/ijrr.20230460 ABSTRACT Background: Cardiovascular diseases are amongst the prime reasons of increasing morbidity as well as mortality worldwide. Dyslipidemia is an important and modifiable risk factor of CVD and statins are extremely endorsed in its treatment. Method: Data was acquired from the online edition of “Current Index of Medical Specialties” (CIMS), 1mg, netmeds. The percentage cost variation as well as cost ratio were calculated. Result: Percentage cost variation was recorded highest in atorvastatin 10mg (3668.50%) whereas, the least percentage cost variation was recorded for pravastatin 10mg (3.61%). Conclusion: To reduce the burden on patients, the government should cover as many as possible drugs under the drug price control order (DPCO) and develop uniformity in the pricing of the drugs. Keywords: Hypolipidemic drugs, cardiovascular diseases, cost variation, statins, brands INTRODUCTION India has evolved to be a kernel for multiple number of pharmaceutical enterprises. It is, in fact, one of the greatest pharmaceutical markets globally owing to the country’s lower cost resources and for producing low- cost high quality generic medicines. Indian pharmaceutical market is ranked third when compared globally and in terms of value and production scale it stands on 13 th number. [1] With reference to generic drug supply, it is leading as well as growing tremendously and has secured its place among one of the biggest suppliers in the world (20% of the volume of global generic drug experts). [2] In India, multiple pharmaceutical industries manufacture same drug at different prices which ends up in widespread variation in the price. This makes it strenuous for both the prescribers as well as the patients to choose the product which fits them the best. On August 29, 1997, the Indian government constituted the National Pharmaceutical Pricing Authority (NPPA) which implemented the national pharmaceutical pricing policy in 2012, followed by the Drug Prices Control Order in 2013, and finally the Jan Aushadi Scheme (JAS) in 2018 to control the hiking prices of medicine. [3,4] However, considering the present circumstances, the price of drugs in the Indian market differs considerably. In accordance with world health organization WHO, health expenditures pose a significant strain on country’s economy. In 2019 India’s health spending was anticipated to be around 64 US $per capita. [5] In addition, over a 10-year period, the nation suffered from wreckage of approx. 237 billion $ in healthcare costs as well